Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics

Journal of Psychopharmacology
David J Nutt, S M Stahl

Abstract

The non-benzodiazepine GABA(A) receptor modulators ('Z-drugs') - zaleplon, zolpidem, zopiclone and eszopiclone - have become the accepted treatments for insomnia where they are available. However, recent randomized, placebo-controlled trials suggest that, for these drugs, there may be particular efficacy and tolerability profiles and distinct clinical outcomes in specific patient populations. This is particularly apparent when hypnotic/ selective serotonin reuptake inhibitor co-therapy is used to treat patients with co-morbid insomnia and psychiatric disorders, as patient recovery appears to be accelerated and enhanced by some drugs but not others. Emerging evidence of why this should be the case is that these hypnotic drugs may differ significantly from each other in their pharmacodynamic and pharmacokinetic profiles. Functional selectivity for specific GABA(A) receptor subtypes may determine each drug's clinical attributes, while the pharmacokinetic characteristics of Z-drugs also determine to a large extent how they perform in the clinic. For example, activity at GABA(A) alpha 1 receptor subtypes may be associated with sedative effects, whereas activity at alpha 2 and alpha 3 receptor subtypes may be associated with anxiolyt...Continue Reading

References

Sep 1, 1990·Hospital Practice·A Kales
Jul 1, 1990·International Clinical Psychopharmacology·C C Ngen, R Hassan
Oct 1, 1985·Pharmacology, Biochemistry, and Behavior·L JulouJ F Dreyfus
May 1, 1995·Trends in Pharmacological Sciences·G B Smith, R W Olsen
Apr 1, 1997·Clinical Neuropharmacology·J C WareG W Vogel
Jul 1, 1997·General Hospital Psychiatry·M M WeissmanW C Dement
Nov 5, 1999·The Journal of Clinical Psychiatry·G M AsnisJ K Walsh
Nov 23, 2000·British Journal of Pharmacology·F CrestaniU Rudolph
Feb 24, 2001·Journal of Psychopharmacology·M L Bocca, P Denise
Mar 29, 2001·European Journal of Pharmacology·J N CarlsonT P Jerussi
May 17, 2001·Proceedings of the National Academy of Sciences of the United States of America·I ToblerU Rudolph
Jul 27, 2001·The Journal of International Medical Research·S Tsutsui, UNKNOWN Zolipidem Study Group
Jan 5, 2002·European Journal of Pharmacology·Hideaki NoguchiToshiharu Shiba
Feb 20, 2002·British Journal of Clinical Pharmacology·Barbara M StonePhilippe Danjou
Mar 21, 2002·The Journal of Pharmacy and Pharmacology·Christine FernandezFrançois Gimenez
Jul 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Mark W Fleck
Jul 27, 2002·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Anne Lingford-HughesDavid J Nutt
Sep 17, 2002·European Journal of Pharmacology·Enrico SannaGiovanni Biggio
Nov 16, 2002·Psychopharmacology·Lance R McMahonCharles P France
Mar 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·C KoppI Tobler
Jul 30, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Carolien van RijnsoeverFlorence Crestani
Aug 25, 2004·The Journal of Clinical Psychiatry·Michael L PerlisJames K Walsh
Jan 19, 2005·British Journal of Pharmacology·John R AtackGerard R Dawson
Feb 11, 2005·Current Medical Research and Opinion·Gary K ZammitThomas Roth
Oct 29, 2005·The Journal of Comparative Neurology·Clifford B SaperThomas E Scammell
Nov 18, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Rebecca DiasDavid S Reynolds

❮ Previous
Next ❯

Citations

Nov 17, 2010·Molecular Psychiatry·B LuscherN Sahir
Jan 13, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Paolo BetticaDerk-Jan Dijk
Mar 26, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ruani N FernandoPatrik Ernfors
Jan 2, 2013·Dementia and Geriatric Cognitive Disorders Extra·Jean-François MorinCarol Hudon
Feb 7, 2012·Bioanalysis·Milena Araújo Tonon, Pierina Sueli Bonato
Oct 29, 2013·Annual Review of Pharmacology and Toxicology·Uwe Rudolph, Hanns Möhler
Feb 14, 2013·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Naren Gunja
Mar 5, 2013·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Naren Gunja
Mar 20, 2012·Expert Opinion on Pharmacotherapy·David J Greenblatt, Thomas Roth
Nov 7, 2012·Expert Opinion on Drug Metabolism & Toxicology·David J Greenblatt, Gary K Zammit
Feb 10, 2016·Human Psychopharmacology·Gosia LipinskaKevin G F Thomas
Jan 31, 2016·European Journal of Pharmacology·Pawel MierzejewskiPrzemyslaw Bienkowski
Sep 1, 2015·Journal of Medicinal Chemistry·Anthony J RoeckerPaul J Coleman
Sep 4, 2012·Clinics in Laboratory Medicine·Hoi-Ying Elsie Yu
May 5, 2011·European Journal of Pharmacology·Robert N PechnickInna Spivak
Dec 6, 2012·ISRN Pharmacology·Ashley Proctor, Matt T Bianchi
Mar 31, 2015·British Journal of Pharmacology·Christine L DixonAngelo Keramidas
Jun 24, 2015·European Journal of Pharmacology·Se Jin JeonJong Hoon Ryu
Mar 22, 2014·Sleep Disorders·Joseph V PergolizziManinder Chopra
May 21, 2013·Neurobiology of Disease·David J Nutt, Jim Attridge
Mar 19, 2014·Neuron·Sha LiuMark N Wu
Jun 5, 2013·Journal of Biomolecular Structure & Dynamics·Hsin-Yi ChenCalvin Yu-Chian Chen
Aug 9, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·A ChagraouiF Thibaut
Sep 28, 2016·Case Reports in Critical Care·Zarah JordahnFrank Christian Pott
Feb 13, 2018·Frontiers in Neural Circuits·Xiao YuWilliam Wisden
Jul 3, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Norikazu KikuchiShinji Hidaka
Feb 23, 2019·Expert Opinion on Pharmacotherapy·Morohunfolu Akinnusi, Ali A El Solh
Mar 1, 2018·Pharmacological Reviews·Tobias AtkinGabriella Gobbi
Mar 24, 2020·Expert Opinion on Therapeutic Patents·Letizia Crocetti, Gabriella Guerrini
Dec 21, 2019·The Mental Health Clinician·Megan Ehret
Nov 7, 2012·Analytical and Bioanalytical Chemistry·Milena Araújo TononPierina Sueli Bonato
Aug 4, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrew D Krystal
Mar 2, 2018·Therapeutic Advances in Psychopharmacology·Simon J C DaviesPaul Kurdyak

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.